Recognizing patients with (a higher risk of) endometrial cancer; the role of fat distribution and inflammation in the origin of endometrial cancer, a study that focuses on prevention and prediction

No registrations found.

Ethical review Positive opinion

Status Pending

Health condition type

Study type Observational non invasive

Summary

ID

NL-OMON28456

Source

NTR

Brief title

ENDOCRINE

Health condition

Endometrial cancer

Sponsors and support

Primary sponsor: AAF (Academic Alliance Foundation)

Source(s) of monetary or material Support: Academic Alliance Foundation

Intervention

Outcome measures

Primary outcome

To compare hormone levels and inflammatory markers before and after BSO in obese and non-obese subjects.

Secondary outcome

To compare the effect of fat distribution and etiology on changes in hormone levels and inflammatory markers due to BSO in obese and non-obese subjects as well as the effect of BSO on menopausal complaints.

Study description

Background summary

The impact of BMI and fat distribution (subcutaneous vs. visceral) on hormone levels and inflammation is not clear. Yet, understanding these interactions in general is highly relevant, and in particular for better understanding and treatment of endometrial cancer (EC) in increasingly obese patients. Standard surgical treatment of EC and of adnexal masses gives access to both the subcutaneous and the visceral adipose tissue, and facilitates to study these important relations. We hypothesize that BMI, the type of fat distribution, and possibly the underlying illness significantly influence the change in hormone levels, and systemic inflammation levels after bilateral salpingo-oophorectomy (BSO). In EC patients , systemic inflammation markers are expected to be higher compared to controls. Also, we expect the ratio of visceral:subcutaneous fat to be higher in these women, as visceral fat tissue is considered to be more metabolic active. Finally, we expect that BSO in obese women result in only slight decrease in estrogen levels.

Study objective

We hypothesize that BMI, the type of fat distribution, and possibly the underlying illness significantly influence the change in hormone levels, and systemic inflammation levels after bilateral salpingo-oophorectomy (BSO). In EC patients , systemic inflammation markers are expected to be higher compared to controls. Also, we expect the ratio of visceral:subcutaneous fat to be higher in these women, as visceral fat tissue is considered to be more metabolic active. Finally, we expect that BSO in obese women result in only slight decrease in estrogen levels.

Study design

Pre-operation, during operation, 6 weeks after operation

2 - Recognizing patients with (a higher risk of) endometrial cancer; the role of fat ... 9-05-2025

Intervention

Preoperatively: All included subjects are requested to consent for blood sample analysis, undergoing CT-scan and fill in three questionnaires. During surgery, fat tissue and (in cases) tumour tissue will be collected. Six weeks after surgery blood will be obtained from all subjects once more and one questionnaire repeated.

Contacts

Public

MUMC

Anouk van den Bosch

0630575778

Scientific

MUMC

Anouk van den Bosch

0630575778

Eligibility criteria

Inclusion criteria

- CASES (n=80): pre- and perimenopausal BMI ≥35 (n=20)
- pre- and perimenopausal BMI 18-25 (n=20)
- postmenopausal BMI ≥35 (n=20)
- postmenopausal BMI 18-25(n=20)

Exclusion criteria

- Other malignancy <5 years prior to inclusion, except basal cell carcinoma
- Use of systemic hormonal therapy <3 months
- Insufficient understanding of the Dutch language
- Subjects not allowed to undergo CT-scan
- Women (cases as well as controls) with BMI between 25.1-34.9
- Women who are expected to be offered HRT after surgery

CONTROLS (n=80): - Pre- and perimenopausal BMI \geq 35 (n=20)

- Age >40 years
 - 3 Recognizing patients with (a higher risk of) endometrial cancer; the role of fat ... 9-05-2025

- pre- and perimenopausal BMI <25 (n=20)
- postmenopausal BMI ≥35 (n=20)
- postmenopausal BMI 18-25(n=20)

Study design

Design

Study type: Observational non invasive

Intervention model: Other

Allocation: Non-randomized controlled trial

Masking: Open (masking not used)

Control: N/A, unknown

Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 01-08-2021

Enrollment: 160

Type: Anticipated

IPD sharing statement

Plan to share IPD: Undecided

Ethics review

Positive opinion

Date: 23-07-2021

Application type: First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

NTR-new NL9622

Other METC AZM/UM : METC 21-011

Study results